Summary
Stryker Corporation's third quarter 2014 report indicates a significant increase in net sales, up 11.1% year-over-year, driven by acquisitions and solid organic growth across its segments, particularly MedSurg and Neurotechnology and Spine. However, net earnings experienced a substantial decline of 44.7%, largely due to a one-time tax charge related to establishing a European regional headquarters and planned cash repatriation, alongside the ongoing impact of product recall charges. The company continued its strategic acquisition spree, adding Small Bone Innovations (SBi), Berchtold Holding, and Patient Safety Technologies (PST) to its portfolio in 2014, enhancing its offerings in reconstructive and MedSurg segments. While balance sheet strength remains, with a healthy current asset to liability ratio, the company is managing increased debt levels following recent note issuances to fund its growth initiatives. Investors should note the significant impact of non-recurring charges on reported earnings, highlighting the importance of examining adjusted figures for a clearer view of underlying operational performance.
Financial Highlights
50 data points| Revenue | $2.39B |
| Cost of Revenue | $829.00M |
| Gross Profit | $1.56B |
| R&D Expenses | $153.00M |
| SG&A Expenses | $878.00M |
| Operating Expenses | $1.11B |
| Operating Income | $450.00M |
| Net Income | $57.00M |
| EPS (Basic) | $0.16 |
| EPS (Diluted) | $0.16 |
| Shares Outstanding (Basic) | 378.40M |
| Shares Outstanding (Diluted) | 382.50M |
Key Highlights
- 1Net sales increased by 11.1% to $2.389 billion for the third quarter of 2014, driven by acquisitions and robust organic growth.
- 2Net earnings significantly decreased by 44.7% to $57 million ($0.16 per diluted share) compared to $103 million ($0.27 per diluted share) in the prior year quarter, largely due to a $300 million tax charge.
- 3The company completed three strategic acquisitions in 2014: Small Bone Innovations (SBi), Berchtold Holding, and Patient Safety Technologies (PST), expanding its product offerings.
- 4Significant recall charges related to the Rejuvenate and ABG II hip stems and the Neptune Waste Management System continued to impact results, although the magnitude decreased compared to the prior year.
- 5Selling, general, and administrative expenses decreased by 19.9% for the quarter, partly due to a significant reduction in recall-related charges compared to the prior year.
- 6Stryker's balance sheet remains strong, with total assets increasing to $17.515 billion and current assets significantly exceeding current liabilities.
- 7The company reported strong debt issuance, including $600 million in senior unsecured notes due 2024 and $400 million due 2044, to fund growth and general corporate purposes.